Codexis Inc., an enzyme engineering company, has entered into an asset purchase agreement with Crosswalk Therapeutics for the company’s investigational Fabry and Pompe disease compounds. Under the terms of the agreement, Codexis is eligible to receive future development and commercial milestone payments in addition to a low-to-mid single-digit percentage net sales-based royalty. “We’re thrilled to place these exciting programs in highly experienced hands at Crosswalk Therapeutics. Since ...